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RNA viruses exhibit extraordinarily high mutation rates during genome replication. Nonnatural ribonucleosides
that can increase the mutation rate of RNA viruses by acting as ambiguous substrates during replication have been
explored as antiviral agents acting through lethal mutagenesis. We have synthesized novel N-6-substituted purine
analogues with ambiguous incorporation characteristics due to tautomerization of the nucleobase. The most potent
of these analogues reduced the titer of poliovirus (PV) and coxsackievirus (CVB3) over 1,000-fold during a single
passage in HeLa cell culture, with an increase in transition mutation frequency up to 65-fold. Kinetic analysis of
incorporation by the PV polymerase indicated that these analogues were templated ambiguously with increased
efficiency compared to the known mutagenic nucleoside ribavirin. Notably, these nucleosides were not efficient
substrates for cellular ribonucleotide reductase in vitro, suggesting that conversion to the deoxyriboucleoside may be
hindered, potentially limiting genetic damage to the host cell. Furthermore, a high-fidelity PV variant (G64S) displayed
resistance to the antiviral effect and mutagenic potential of these analogues. These purine nucleoside analogues represent
promising lead compounds in the development of clinically useful antiviral therapies based on the strategy of lethal
mutagenesis.
Natural nucleotides exist as tautomers in solution, and tau-
tomerization of the nucleobases in DNA has been recognized
as a likely mutagenic mechanism ever since the double-helical
structure of the DNA molecule was first deduced by Watson
and Crick (33, 36). The keto (for G and U) and amino (for A
and C) tautomers of the natural nucleotides are the predom-
inant species with tautomeric constants (KT) on the order of
105. However, tautomeric conversion to the rare enol or imino
forms of the nucleobases can lead to altered hydrogen bonding
specificity and thus mutagenesis through noncanonical base-
pairing interactions. This has become known as the “rare tau-
tomer” hypothesis of mutation (19, 29).
The tautomerization of bases to yield ambiguous base-pair-
ing properties has also been exploited in the design of novel
nucleoside drugs, including 5-hydroxy-2-deoxycytidine (22)
and 5-aza-5,6-dihydro-2-deoxycytidine (KP-1212) (18, 25)
(Fig. 1A). However, attempts to design clinically useful antivi-
ral compounds around this premise have met with only limited
success (13, 16, 18, 25).
Nucleobases exhibiting multiple conformations due to rota-
tion or tautomerization have received attention as potential
antiviral agents acting through lethal mutagenesis (11, 22).
Since the discovery that ribavirin (Fig. 1B) can act as a lethal
mutagen (7), likely through rotation of the exocyclic carbox-
amide moiety, the concept of lethal mutagenesis as an antiviral
strategy has received considerable attention (5, 11, 12).
Recently, we have demonstrated that the ribonucleoside an-
alogue rP (Fig. 1C) can act as a potent mutagen of poliovirus
(PV) in vitro (13). Tautomerization of the nucleobase of rP
(KT, 10) allows it to be recognized as either cytosine or uracil
by the PV RNA-dependent RNA polymerase (RdRp) 3Dpol,
though its effectiveness as an antiviral molecule in vivo is hin-
dered by the lack of accumulation of the active metabolite,
rPTP (13).
The nucleobases K and Z have previously been examined as
ambivalent purine analogues with tautomerization constants
near unity (4). Deoxyribonucleosides containing these bases
(dK and dZ) have been synthesized and were found to induce
transition mutations in PCRs using Taq polymerase (4, 20). dK
favors the imino (or “G-like”) tautomer by a ratio of 9:1,
subsequently inducing transition mutations efficiently in Esch-
erichia coli (20). Likewise, dZ favors the imino tautomer by a
ratio of 4:1, though it is a less effective mutagen in vivo (4, 20).
A library of N-6-substituted purines designed on this premise
has recently been synthesized and evaluated for antimalarial
properties (32).
Herein, we examine the corresponding ribonucleosides rK
and rZ, (hereafter referred to as JA31 and JA26, respectively)
and analogues thereof as lethal mutagens of picornaviruses.
We demonstrate that the most potent of these analogues are
able to reduce the titer of PV and coxsackievirus B3 (CVB3) in
cell culture over 1,000-fold during a single passage. Treatment
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with these analogues was able to increase the frequency of
transition mutations by more than 50-fold over a single pas-
sage, as measured by a phenotypic assay, suggesting a role of
lethal mutagenesis in the observed antiviral activity. Impor-
tantly, these nucleosides are substrates for cellular kinases,
resulting in accumulation of the triphosphorylated species that
is the necessary substrate for incorporation into viral genomic
RNA. Furthermore, diphosphates of the active analogues were
poor substrates of mammalian ribonucleotide reductase, sug-
gesting that they may not be converted to intracellular deoxy-
ribonucleotides, lessening the chance of permanent genetic
damage to cells replicating their DNA in the presence of these
nucleosides. Therefore, these purine analogues represent
promising new lead compounds for the translation of mutagen-
esis-based antiviral strategies to clinical use.
MATERIALS AND METHODS
Cells and viruses. HeLa S3 cells (obtained from ATCC) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 medium supplemented
with 2% dialyzed fetal bovine serum and 1 penicillin-streptomycin (Invitro-
gen). Cells were maintained at 37°C in a 5% CO2 atmosphere. Antiviral activity
assays were performed as previously described (16, 17). PV was generated by
transfecting HeLa S3 cells with full-length genomic RNA transcribed using T7
RNA polymerase from a plasmid containing the viral cDNA (pMoRA) as pre-
viously described (1, 35). CVB3 was similarly produced using RNA transcribed
from plasmid pSV-CVB3/0 (6) (a gift from N. Chapman and S. Tracy, University
of Nebraska Medical Center). The guanidine resistance (Guar) assay was per-
formed as previously described (7). Statistical analysis was performed using
Prism 4 for Windows (GraphPad Software, Inc.).
Incorporation of nucleotide analogues by PV 3Dpol. Efficiency of incorporation
by poliovirus polymerase (3Dpol) opposite each of the four templating bases in
assembled enzyme-symmetrical primer-template substrate (s/s) complexes was
examined for each of the seven nucleotide analogues, ribavirin, the correct
natural nucleotide, and the natural nucleotide giving rise to a transition muta-
tion. Ribavirin triphosphate (RTP) was purchased from Moravek Biochemicals.
PV 3Dpol was expressed and purified as previously described (10). Extension
assays utilizing symmetrical primer-template substrates (s/s) were performed as
described (1). s/s RNAs were synthesized by Dharmacon, Inc. The sequences of
RNA oligonucleotides were as follows (the templating base in the duplex sub-
strate is indicated in boldface): s/s-U, 5-GCAUGGGCCC-3; s/s-C, 5-GAUC
GGGCCC-3; s/s-A, 5-GCUAGGGCCC-3; and s/s-G, 5-CAUGCCCGGG-3.
RNA oligonucleotides were 5-end labeled using [-32P]ATP and T4 polynucle-
otide kinase according to the manufacturer’s protocol (New England BioLabs).
Annealing of 32P-end-labeled and unlabeled s/s oligonucleotides to form primer/
template duplex was accomplished by heating to 90°C for 1 min followed by
cooling to 10°C at a rate of 5°C per min. 3Dpol was allowed to preassemble with
s/s duplex for 3 min at room temperature before initiation by addition of the
nucleotide substrate. Reactions were performed at 30°C for 60 s or 330 s in 50
mM HEPES (pH 7.5), 10 mM 2-mercaptoethanol, 5 mM MgCl2, 60 M ZnCl2,
2 M 3Dpol, 0.5 M s/s duplex, and 0.5 mM NTP. Reaction products were
separated by denaturing polyacrylamide gel electrophoresis (PAGE), and gels
were visualized using a PhosphorImager and quantified using ImageQuant soft-
ware (Molecular Dynamics) as previously described (1).
Chain termination assays. Complexes of 3Dpol and s/s-U duplex were preas-
sembled as described above. Reaction conditions were as described above, ex-
cept the reaction time was 180 s and reactions were initiated with either 0.5 mM
ATP or nucleotide analogue or with 0.5 mM ATP or analogue and 10 M UTP.
Reaction products were separated, visualized, and quantified as described above.
Cytotoxicity assays. HeLa S3 cells were propagated in DMEM/F-12 (Invitro-
gen) supplemented with 2% fetal bovine serum (Invitrogen) and 1% penicillin-
streptomycin (Invitrogen), with the cultures maintained between 20% and 80%
confluence. Subconfluent monolayers of HeLa S3 cells were detached from the
culture flasks by trypsin treatment and washed with 1 phosphate-buffered
saline (Invitrogen), and the cell number was adjusted to 2  103 cells per 50 l
of DMEM/F-12. Fifty microliters of cell suspension was cultured in a 96-well
plate, with one row serving as a negative control with no cells. The plate was
incubated for 1 h at 37°C to allow cell adherence. Fifty microliters of the
compound of interest diluted in DMEM/F-12 was added to the HeLa S3 cells,
and the plate was incubated at 37°C. Six hours before a desired time point, 20 l
of the CellTiter-Blue reagent (Promega), resazurin, was added to triplicate series
of wells. After 6 h of incubation, the A570 and A590 were measured using an
HTSoft Bioassay plate reader (HTSoft). The 590-nm reading served as a refer-
ence wavelength to correct for the partial interference of unreduced reagent in
the 570-nm reading. The following equation was used to determine the percent-
age of resazurin reduced: % reduced  A570  (A590  R0)  100. The correc-
tion factor R0 is the ratio of resazurin absorbances at different wavelengths: R0 
AO570/AO590, where AO	  (absorbance of medium  resazurin)	  (absor-
bance of medium)	.
Detection of nucleotides in HeLa S3 cells. Cell extracts were prepared and
analyzed based on previously published methods (13, 30). HeLa S3 cells were
adapted to suspension and maintained in spinner flasks at a density of 1 106 to
2 106 cells/ml in S-MEM (minimum essential medium modified for suspension
cultures) containing 10% fetal bovine serum, 2 mM L-glutamine, 50 U/ml pen-
icillin, and 50 g/ml streptomycin (Invitrogen). Cell density was adjusted to 5 
106 cells/ml immediately prior to treatment in S-MEM, to which was added 2%
dialyzed fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml
streptomycin. Cells were treated with 2.5 g/ml actinomycin D (Sigma) for 15
min at 37°C, and then nucleotide was added to the medium to a final concen-
tration of 0.5 mM. One percent dimethyl sulfoxide (DMSO) was present in both
treated and control samples. Samples were incubated for 2 h at 37°C in a Lauda
circulating water bath with occasional mixing by inversion. Cells were collected
by centrifugation at 2,000  g for 4 min and washed with 2 volumes phosphate-
buffered saline. Cells were then pelleted and resuspended in 1 volume ice-cold
0.6 M trichloroacetic acid (Sigma). The cell suspension was incubated on ice for
10 min and then centrifuged at 14,000  g for 2 min at 4°C. The supernatant was
collected and extracted with an equal volume of ice-cold 0.5 M trioctylamine in
1,1,2-trichlorotrifluoroethane (Sigma). Samples were then vortexed for 30 s and
centrifuged for 30 s at 14,000  g and 4°C.
The upper (aqueous) layer of the cell extract was analyzed on a Hewlett
Packard 1100 series instrument equipped with an Aquasil C18 analytical column
(4.6  250 mm, 5 m; Keystone Scientific, Inc. [Thermo Electron Corp.])
running a mobile phase (flow rate of 1 ml/min) gradient of 1% to 15% CH3CN
in KH2PO4 buffer (pH 6.0, 0 to 20 min) and 15% to 80% CH3CN in KH2PO4
buffer (20 to 30 min). All injections were 50 l.
Preparation of E. coli R1 and R2. The R1-containing plasmid was a kind gift
of Jeff Baldwin. The E. coli R1 gene was amplified from the K-12 strain by colony
PCR using primer 1 (5-CATATGAATCAGAATCTGC; NdeI site in boldface)
and primer 2 (5-TACGCCGCATCCGGCATCTCGAGATCA; XhoI site in
boldface). The 2,315-bp PCR product was purified by agarose gel electrophoresis
followed by gel extraction using the Qiagen (Valencia, CA) QiaQuick system.
Due to a second internal NdeI site in the gene, the restriction digest produced
two fragments (996 bp and 1,300 bp). These fragments were both Qiagen kit gel
purified and included in the ligation reaction with NdeI/XhoI-cut pET22b. After
transformation of the plasmid (ligation mix) into the DH5
 cell line, several
colonies were selected from the culture plate and grown in LB-ampicillin (0.15
mg/ml) to an optical density (OD) of 1 to 2, and the cells were harvested for
plasmid using the Promega (Madison, WI) Wizard mini-prep kit. Sequencing was
then employed to find the plasmid with gene fragments in the correct orientation.
Construction of plasmid pET22b-R2 has been described elsewhere, as have R2
expression and purification (27).
BL21(DE3) cells carrying the plasmid pET22b-R1 were grown at 37°C in rich
LB broth containing 35 g/liter tryptone, 20 g/liter yeast extract, 5 g/liter NaCl, and
0.15 g/liter ampicillin to an OD600 of 0.7 to 1.0 and then cooled on ice for 15 min,
FIG. 1. Structures of mutagenic nucleoside analogs. (A) 5-Aza-5,6-
dihydro-2-deoxycytidine (KP-1212), imino tautomer. (B) Ribavirin.
(C) P, imino tautomer. R denotes deoxyribose (KP-1212; dP) or ribose
(ribavirin; rP).
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induced by addition of 0.2 mM isopropyl--D-thiogalactopyranoside (IPTG), and
grown for 16 to 18 h at 15°C. The cells were then harvested by centrifugation, and
the pellet was washed with buffer (25 mM Tris-Cl [pH 7.4], 70 mM NaCl, 4 mM
KCl) prior to being frozen in liquid nitrogen and stored at 80°C. A typical yield
produces 20 g of wet paste/liter of culture.
The frozen cells (60 g wet paste) were thawed in a mixture of 50 mM Tris-Cl
(pH 7.6), 5% (vol/vol) glycerol, 15 mM magnesium acetate, and 4 mM dithio-
threitol (DTT) (buffer A) containing 0.25 mM phenylmethylsulfonyl fluoride and
lysed in a French pressure cell at 16,000 lb/in2. Cell debris was removed by
centrifugation at 14,000  g for 10 min. Streptomycin sulfate was added to a final
concentration of 1% (wt/vol). The precipitate was removed by centrifugation at
13,900  g for 10 min. The supernatant was dialyzed against 4 liters buffer A and
was diluted with an equal volume of buffer A containing 0.25 mM phenylmeth-
ylsulfonyl fluoride. The solution was then loaded onto a 1.25- by 37-cm (0.046
liter) Affi-blue gel column (Bio-Rad) equilibrated in buffer A, and the protein
was eluted with a 0.46-liter linear gradient of 0 to 0.5 M NaCl at a flow rate of
1 ml/min. Fractions containing R1 were pooled and concentrated by ultrafiltra-
tion in an 350-ml Millipore (Billerica, MA) Amicon cell equipped with a YM30
membrane. The protein was dialyzed against 50 mM HEPES buffer (pH 7.6)
containing 10% (vol/vol) glycerol, 15 mM magnesium acetate, and 4 mM DTT,
flash-frozen in liquid nitrogen, and stored at 80°C.
Preparation of mouse R1 and R2. Expression and purification of R2 were
performed as previously described (38). Plasmid pMR1, which contains the mouse
R1 gene inserted into the pET22b expression vector, was constructed as follows.
The mouse R1 gene was amplified by PCR from the pET3 vector containing the
mouse R1 gene. Primer 1 (5-GGCGTGCATATGCATGTGATCAAGCGAGAT
GGCCGC-3; NdeI site shown in boldface) and primer 2 (5-CATCAACATGTG
CTGCGGCCGTTCAGCCACTTTACC-3; EagI shown in boldace) were used to
amplify a 527-bp fragment (fragment 1) and remove an endogenous NdeI site (ATG
to GTG [underlined]). Fragment 1 was purified by agarose gel electrophoresis,
extracted using the QiaQuick system, restricted with NdeI and EagI, and repurified.
The second fragment (fragment 2) of the mouse R1 gene was PCR amplified
using primer 3 (5-GGTAAAGTGGCTGAACGGCCGCAGCACATGTTGATG-
3; EagI site shown in boldface) and primer 4 (5-CGCATATAGCTCGAGCTCA
GGATCCACACATCAGGCACTCC-3; XhoI shown in boldface). The 1,919-bp
fragment 2 was gel purified, restricted with EagI and XhoI, repurified, and ligated to
the cut fragment 1 and pET22b, which had been restricted with NdeI and XhoI and
gel purified. BL21(DE3) cells were transformed with the pMR1 plasmid.
The purification method for mouse R1 was performed as described for E. coli
R1, and it typically yielded 0.5 mg of protein per g of wet cell mass.
Mass spectrometry analysis of dNDP production by RNR catalysis. The assay
was performed as previously described (21). At 22°C, 8.8 M E. coli R2 was
added to a 200-l reaction mixture consisting of 100 mM HEPES (pH 7.6), 1.7
mM dTTP, 1.8 mM 5-dNDP analog, 15 mM magnesium acetate, 1 mM EDTA,
25 mM DTT, and 5 M E. coli R1. The reaction was quenched by filtration
through an Amicon Microcon YM-3 filter (Millipore, Bedford, MA). The filtrate
was then measured by direct injection onto a Waters Micromass ZQ 2000 mass
spectrometer operating in ES mode. For a zero-minute time, a portion of the
total mix was filtered and measured prior to the addition of R2. The procedure
for assaying mouse ribonucleotide reductase (RNR) for activity was the same as
that for E. coli, with the exception of that eightfold more RNR was used (40 M
mouse R1 and 86 M mouse R2).
RESULTS
Synthesis of N-6-substituted nucleoside and nucleotide an-
alogues. The synthesis of dK and dZ has previously been re-
ported (4). The ribonucleotides containing the K and Z
nucleobases, as well as the suite of related analogues shown in
Fig. 2, were synthesized as reported previously (32). Further-
more, di- and triphosphorylated species (illustrated in Fig. S1
in the supplemental material) were synthesized. The results of
biological and biochemical testing of these compounds are
summarized in Table 1.
Antiviral activity against PV and CVB3. The purine ribonu-
cleoside analogues were initially screened for antiviral activity
in HeLa S3 cells against two picornaviruses, PV and CVB3.
FIG. 2. Structures of N-6-modified purine nucleoside analogues.
TABLE 1. Biological and biochemical properties of
nucleoside analoguesa
Nucleoside
% Reduction
in titerb
% Cell
viability
(HeLa S3)b
Fold
Guar
increasec
%
Triphosphate
incorporation
by PV 3Dpold
PV CVB3 vs U vs C
RBV 98 98 75 74 0.13 —f
JA24 97 95 57 1.9 0.9 0.92
JA23 88 11 NDe ND 0.54 0.1
JA25 99.7 99.9 56 1.8 ND ND
JA27 35 0 ND ND 0.54 0.02
JA28 98 97 61 35 0.92 0.94
JA26 81 22 ND ND 0.79 0.18
JA30 99.97 99.997 37 65 0.89 0.65
JA31 45 0 ND ND 0.92 0.31
a For antiviral and cytotoxiciy studies, the JA25 and JA28 data shown are for
0.5 mM treatment. All other analogues are from the 2 mM treatment.
b Results are reported as percent reduction in titer or percent viability com-
pared to untreated control. Cellular toxicity was measured via Alamar blue assay
after 24 h of continuous exposure.
c Increase in guanidine-resistant virions compared to untreated infection.
d Percent incorporation relative to the correct, natural nucleotide after 60 s.
e ND, not determined.
f —, below the limit of detection.
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HeLa S3 cells were pretreated with each nucleoside for 1 h
prior to infection to allow for accumulation of intracellular
metabolites. The known mutagenic nucleoside ribavirin was
assayed in parallel for comparison. All nucleosides were eval-
uated at both 0.5 and 2 mM. Cells were then infected with
either virus at a multiplicity of infection (MOI) of 5. Fresh
medium containing nucleoside analogue was then added to the
cells, and the infection was allowed to proceed for 6 h at 37°C.
Cell-associated virus was collected after incubation, and the
titer was determined on HeLa S3 monolayers.
The results of the antiviral activity screen are shown in Fig.
3. Ribavirin and four N-6-substituted purine analogues (JA24,
JA25, JA28, and JA30) elicited a reduction in virus titer of
greater than 90%. Addition of a methyl group to the N-6
substituent (see JA23, JA27, JA26, and JA31) reduced the
antiviral properties of each nucleoside. Compared with JA24,
JA25, and JA28, the presence of a methyl group in JA23, JA26,
and JA27 reduced antiviral activity 3- to 5-fold against PV and
5- to 30-fold against CVB3 at the highest concentration tested
(2 mM). Examination of JA25 and JA28 at the 0.5 mM treat-
ment revealed that presence of the methyl group reduced an-
tiviral activity 130- and 15-fold against PV and 160- and 60-fold
against CVB3, respectively. The activity of JA30 was most
highly impacted by the presence of a methyl group as in JA31,
showing 2,000-fold and 40,000-fold reductions in activity
against PV and CVB3, respectively, at the 2 mM treatment.
Cytotoxicity of analogues exhibiting antiviral activity. While
reduction in titer may be indicative of specific antiviral activity,
treatment of cells with nucleoside analogues may also have
toxic effects that can cause an apparent, yet nonspecific, reduc-
tion in titer. Evaluation of cytotoxicity using a typical MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]-
based assay was complicated by cross-reactivity of some analogues
with the assay reagent (data not shown). Instead, an assay based
on the reduction of resazurin (Alamar blue) as a measure of the
metabolic capacity of cells was used. HeLa S3 cells were treated
with medium containing 0.05 to 2 mM of each nucleoside, and
reduction of resazurin was measured after 24 or 48 h of incuba-
tion at 37°C (Table 1 and Fig. 4). The data were normalized such
that resazurin reduction by cells treated only with vehicle
(DMSO) was set to 100%. JA24, JA28, and JA30 all exhibited a
cytostatic effect (50% inhibition at 24 h), whereas JA25 had more
marked toxicity.
Guanidine resistance assay to estimate transition mutation
frequency in PV. If these purine analogues are ambiguous and
base pair efficiently with either of the natural pyrimidines due
to their rapid tautomerization, an increased frequency of tran-
sition mutations for virus grown in their presence should be
observed. Consequently, the antiviral activity of these nucleo-
sides may be attributable to lethal mutagenesis.
To test this hypothesis, we utilized a previously established
assay for guanidine resistance in PV (7). PV replication is
blocked in the presence of 3 mM guanidine hydrochloride due
to inhibition of the 2C protease; however, resistance can be
conferred by a single transition mutation which arises naturally
FIG. 3. Nucleoside analogues are antiviral against PV and CVB3.
HeLa cells were pretreated with nucleoside analogs (at 0.5 or 2 mM)
for 1 h prior to infection with PV or CVB3 at an MOI of 5. Infection
was allowed to proceed for 6 h, at which time cell-associated virus was
collected and the titer was determined. Data were normalized such
that the titer of control sample with no nucleoside treatment was set to
a value of 100.
FIG. 4. Cytotoxicity of nucleoside analogs in HeLa cells. Cytotox-
icity was measured using an Alamar blue-based assay as described in
Materials and Methods. Cells were incubated in the presence of the
nucleoside of interest, and Alamar blue reagent was added 6 h prior to
measuring absorbance (A) 24 (A) or 48 (B) h postexposure. Data were
normalized such that 100% viability was set equal to the percentage of
Alamar blue reagent reduced by untreated cells. Data are presented as
the means and standard deviations from three independent wells. For
each series, the bars represent, from left to right, 0, 0.05, 0.1, 0.5, 1, and
2 mM treatments.
974 GRACI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on A
pril 29, 2015 by U
niversity of K
ansas
http://aac.asm
.org/
D
ow
nloaded from
 
in PV populations at a frequency of approximately 105 (3). If
the mechanism of action of these nucleoside analogues is lethal
mutagenesis, the frequency of Guar variants should increase in
PV populations treated with the analogues.
Guanidine resistance frequency was measured in virus pop-
ulations treated with 2 mM JA24, JA25, JA28, or JA30 (Table
2). The known mutagen ribavirin was included as a control,
and treatment with ribavirin increased the frequency of Guar
variants approximately 75-fold. JA24 and JA25 proved to be
only mildly mutagenic, increasing the Guar frequency only
twofold. However, JA28 and JA30 both showed significant
increases in Guar frequency (35- and 65-fold, respectively).
Incorporation of nucleoside triphosphate analogues in vitro
by PV 3Dpol. To determine whether the mutagenic activity of
the analogues JA24, JA28, and JA30 could be due to incorpo-
ration of the monophosphate of each into RNA and subse-
quent induction of mutagenesis through ambiguous base pair-
ing, the 5-triphosphorylated species of each was synthesized
(see Fig. S1A in the supplemental material). The nucleosides
that lacked substantial antiviral activity (JA23, JA26, JA27,
and JA31) were also triphosphorylated as controls. JA25 was
not further investigated due to its acute cellular toxicity. These
nucleotides, in addition to RTP, were evaluated as substrates
of the PV RNA-dependent RNA polymerase, 3Dpol, using a
primer extension assay which utilizes the s/s RNA duplex (1).
Nucleotides were examined as purine analogues by measuring
in vitro incorporation opposite uridine or cytidine as previously
described (1). Each s/s duplex was end labeled with 32P and
preincubated with PV 3Dpol for 3 min at room temperature to
allow for assembly of stable extension complex. The reaction was
then initiated by addition of nucleotide and incubated at 30°C for
60 or 330 s before quenching with EDTA. Product was separated
via denaturing PAGE, and product was quantitated via
PhosphorImager as previously described (1). Each nucleotide was
also evaluated as a pyrimidine analog by utilizing the appropriate
adenine and guanine s/s templates. No significant incorporation
was detected opposite the natural purines (data not shown).
The results of incorporation of nucleotides via PV 3Dpol are
shown in Table 3. Results were normalized so that the amount
of extended product formed at a given time when the correct,
natural substrate was added was set to a value of 1. All nucle-
otides tested were incorporated more rapidly than the known
ambiguous substrate RTP when uridine was employed as the
templating base, indicating that all nucleotides examined
mimic adenosine as substrates for 3Dpol. However, the ana-
logues containing a methyl substituent at the N-6 position
(JA23, JA26, JA27, and JA31) showed a reduced capacity as
substrates when templated by cytidine. Importantly, both
JA24-TP and JA28-TP showed a high capacity to act as ambigu-
ous substrates; that is, after 60 s of incubation, they were tem-
plated approximately equally well by either uridine or cytidine,
and the amount of product formed under these conditions was at
least 90% of the amount of product formed with the correct
nucleotide. JA30-TP also showed rapid and ambiguous incorpo-
ration characteristics, although it was templated by cytidine at
only 65% of the efficiency of GTP after 60 s of incubation.
Nucleotide analogues are not “chain terminators.” Incorpo-
ration of nonnatural nucleotides into RNA may affect subse-
quent polymerization by blocking further addition of nucleo-
tides to the 3 end of the nascent RNA (“chain termination”).
Additional primer extension assays were employed to deter-
mine whether this mechanism might contribute to the observed
antiviral activity of these nucleoside analogues. PV 3Dpol was
incubated with s/s-U substrate to form active elongation com-
plexes. The reaction was then initiated by addition of the nu-
cleotide analogue of interest combined with 10 M UTP. The
s/s-U primer/template substrate contains an adenosine in the
second template position, allowing UTP to “chase” the 1
RNA reaction product to a 2 (12-mer) product if further
primer elongation is possible (Fig. 5). For each of the nucleo-
tide analogues tested, quantitative conversion of the 1 prod-
uct to 2 product was observed, indicating that incorporation
of these nucleotides does not prevent incorporation of the next
templated nucleotide. Thus, chain termination was not ob-
served after a single incorporation of any of these nucleotide
analogues.
HPLC analysis of intracellular metabolites of JA28. A nu-
cleoside analog must be metabolized to its 5-triphosphate in
order to be incorporated into viral RNA. To assess whether
these purine analogues might be acting via lethal mutagenesis,
we attempted to identify the triphosphorylated species in HeLa
S3 cells treated with the nucleoside. We chose to work with a
potent and efficiently incorporated analogue, JA28. HeLa S3
TABLE 2. Guanidine resistance frequency of PV populations
exposed to nucleoside analogues
Nucleoside Gua
r frequency/
106 PFUa
None .....................................................................................5.4  2.3
RBV......................................................................................400  120
JA24 ......................................................................................10  3.1
JA25 ......................................................................................9.6  6.0
JA28 ......................................................................................190  42
JA30 ......................................................................................350
a Guanidine resistance was measured as previously described (7). Cells were
treated with 2 mM nucleoside analogue prior to infection as described in the text.
Monolayers were infected with 1  106 PFU of PV and incubated in the presence
of 3 mM guanidine hydrochloride, and the number of plaques was determined 3
days later via crystal violet staining. Data are presented as means  standard
deviations from 3 independent samples For JA30, n  2 and standard deviation
was not calculated.
TABLE 3. Nucleotide analogue incorporation into RNA by PV
3Dpol in vitro
Nucleotide or
analogue
Relative incorporation with templating basea:
Uridine Cytidine
60 s 330 s 60 s 330 s
JA23-TP 0.54 0.96 0.1 0.15
JA24-TP 0.9 0.92 0.92 0.9
JA26-TP 0.79 0.79 0.18 0.25
JA27-TP 0.54 0.89 0.02 0.01
JA28-TP 0.92 0.82 0.94 0.9
JA30-TP 0.89 0.8 0.65 0.65
JA31-TP 0.92 0.79 0.31 0.65
RTP 0.13 0.57  0.6
ATP 1 1  
GTP 0.13 0.61 1 1
a Incorporation of analogues was measured by primer extension using PV
3Dpol. For each substrate, incorporation of the correct nucleotide was set to 1. ,
no extension detected. Results for analogues capable of inducing transition
mutations (Table 2) are shown in bold.
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cells were grown in suspension and treated with actinomycin D
(2.5 g/ml) to prevent incorporation of ribonucleotides into
cellular RNA. Cells were then treated with 0.5 mM JA28 for
2 h and extracted as previously described (13, 30). Reversed-
phase high-performance liquid chromatography (HPLC) anal-
ysis of the cell extracts indicated that a substantial amount of
the triphosphorylated species was present (Fig. 6). No mono-
or diphosphorylated species were observed. Retention time
and characteristic UV absorbance trace identified the peak as
JA28-TP compared to HPLC analysis of synthesized material
(compare Fig. 6A to C). The characteristic peak was not
present in the untreated control (Fig. 6B). Thus, JA28 is rec-
ognized by cellular kinases and converted to detectable
amounts of intracellular JA28-TP within 2 h of exposure.
Enzymatic 2-dehydroxylation of nucleoside analogue diphos-
phates by RNR. Intracellular accumulation of triphosphory-
lated forms of nucleoside analogues is essential for lethal mu-
tagenesis via direct incorporation into viral genomic RNA.
However, it is also possible for a nucleoside analogue to be
utilized as a substrate for cellular DNA polymerases if the
ribonucleoside is deoxygenated at the 2 position by cellular
metabolic processes to yield the 2-deoxyribonucleoside-5-
triphosphate (dNTP). Conversion to the deoxyribonucleotide
may allow for incorporation into host cell DNA, increasing the
possibility of nonreversible genetic mutation to the host cell.
The most likely pathway for conversion to the 2-deoxyribo-
nucleotide is through ribonucleotide reductase, a cellular en-
zyme which removes the 2-hydroxyl from a ribonucleoside-5-
diphosphate (rNDP) (26). However, the substrate specificity of
these enzymes is largely undefined. As such, we have devel-
oped an assay to measure the conversion of rNDPs to dNDPs
by monitoring substrate formation and product disappearance
by mass spectrometry in the presence of active RNR from
either E. coli or mouse. We synthesized the ribonucleoside
diphosphates of JA24 (JA53), JA28 (JA51), and JA30 (JA52)
(hereafter referred to as JA24-DP, JA28-DP, and JA-30-DP;
see Fig. S1B in the supplemental material), as well as ribavirin
diphosphate (RDP) for comparison.
Recombinant mouse and E. coli RNRs differed greatly in
their capacity to convert the nucleotide analogues (Table 4).
Although both are in the class I RNR family, mouse RNR was
not able to produce detectable amounts of dRDP or dJA28-
DP, whereas the E. coli RNR catalyzed production of both,
albeit much more slowly than dGDP. RDP was converted at
approximately 46% the rate of rGDP by the E. coli RNR;
JA28-DP was converted only 7% as efficiently as rGDP. Pre-
sumably this discrimination by mouse RNR also exists in other
mammalian systems, including humans, and extends a certain
defense against miscoding. JA24-DP was unstable under these
assay conditions. The JA24-DP mass peak signal decayed with-
out any concomitant production of a deoxy-JA24-DP signal in
the presence or absence of RNR. Thus, the conversion of this
analogue could not be established with the current assay. No-
tably, neither mouse nor E. coli RNR catalyzed conversion of
JA30-DP to detectable levels.
A high-fidelity PV variant is resistant to the mutagenic ef-
fects of JA24, JA28, and JA30. Previously, a PV variant (PV-
G64S) was isolated that demonstrated increased polymerase
fidelity and resistance to the antiviral effects of ribavirin due to
a single amino acid substitution in the 3Dpol coding region (2,
28). This mutation also conferred resistance to 5-azacytidine,
another known mutagenic nucleoside analogue (28). If the
antiviral activity of a nucleoside analogue is due to lethal mu-
tagenesis via incorporation of the nucleotide triphosphate into
viral genomic RNA by the viral polymerase 3Dpol, PV-G64S
may exhibit resistance to the analogue relative to the wild-type
virus (PV-WT).
At the 2 mM concentration, PV-G64S showed resistance to
each of the four nucleotides tested, with titers 1.5- to 3-fold
higher than that of PV-WT when normalized to the untreated
control, which is similar to the resistance seen for ribavirin
treatment at this concentration (Fig. 7A). The treated virus
populations were then assayed for guanidine resistance. PV-
G64S treated with nucleoside analogue demonstrated mark-
edly fewer transition mutations in progeny virions (as esti-
mated by Guar frequency) than the wild-type polymerase (Fig.
7B). The frequency of Guar variants was two- to sixfold lower
for G64S virus than for PV-WT under identical treatment.
These results suggest that the mechanism of antiviral activity of
these nucleosides affects a specific virus target (the viral RNA-
dependent RNA polymerase) and that the activity is mediated,
at least in part, by replication fidelity.
DISCUSSION
Although the N-6-substituted purine analogues described
herein showed more favorable incorporation kinetics than
ribavirin (see Table 2), they were less effective mutagens based
FIG. 5. Nucleotide analogues are not chain terminators. Complexes of 3Dpol and s/s-U were preassembled and then mixed with either 500 M
nucleotide ( lanes) or with 500 M nucleotide and 10 M UTP ( lanes). The reaction was allowed to proceed at 30°C for 180 s, followed by
quenching with EDTA and separation via denaturing PAGE. NTP added is indicated above each lane. The positions of 10-mer substrate and
extended products are indicated to the left.
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on Guar frequency. There are a number of possible explana-
tions for this observation. First, ribavirin monophosphate is a
known inhibitor of cellular inosine monophosphate dehydro-
genase, which should cause a reduction in cellular purine nu-
cleotide pools (most notably GTP). By reducing the concen-
tration of competitor nucleotide, RTP may be able to more
effectively compete with the natural nucleotides present in the
cell. The ability of the JA nucleosides to influence cellular
nucleotide pools by targeting enzymes of cellular nucleotide
metabolism has not yet been investigated. Inosine monophos-
phate dehydrogenase inhibition alone has been demonstrated
to cause an antiviral effect and likely contributes to the muta-
genic activity of ribavirin (9, 24, 31, 37).
Second, the kinetic flux through the cellular nucleotide me-
tabolism pathway may differ between nucleotides. Hence, if
FIG. 6. Analysis of extracts of HeLa S3 cells by reverse-phase HPLC. (A) Analysis of pure JA28-TP including the full UV spectrum of the
JA28-TP peak at 3.6 min (inlay). mAU, milli-absorbance units. (B) Analysis of extracts of untreated HeLa S3 cells including the full UV spectrum
of the eluent at 3.6 min. (C) Analysis of extracts of HeLa S3 cells treated with JA28 (0.5 mM) including the full UV spectrum of the eluent at 3.6
min (inlay). The long-wavelength absorption characteristic of JA28-TP is illustrated by the arrows to the right. Peaks were detected by A325.
TABLE 4. Conversion of nucleoside diphosphates by RNR
Substrate Activator Organism Conversionrate/min
GDP dTTP E. coli 10.5
Mouse 0.3
RDP dTTP E. coli 4.8
Mouse 0.005
JA24-DP dTTP Unstable in DTT
JA28-DP dTTP E. coli 0.75
Mouse 0.005
JA30-DP dTTP E. coli 0.005
Mouse 0.005
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ribavirin is more rapidly converted to the corresponding
triphosphate by cellular metabolism machinery, it may act as a
more potent mutagen due to the higher intracellular concen-
tration of the active metabolite. Finally, the unnatural nucleo-
bases of these analogues may be modified through the action
of other cellular metabolic enzymes to yield bases that have
diminished or absent ambiguous base-pairing capacity. Such
metabolic conversion would reduce the ability of the muta-
genic nucleotide to accumulate within the cell.
The differences observed in antiviral activity between
nucleosides may also be due to subtle differences in the kinet-
ics of incorporation. In the present study, nucleotide incorpo-
ration prior to 60 s was not examined, and thus quantitative
information on the rate of incorporation is currently unknown,
as in some cases the incorporation had reached completion
prior to 60 s. However, we can conclude that JA24, JA28, and
JA30 were all incorporated more rapidly than ribavirin in the
context of either templating pyrimidine.
Modified nucleosides can often exert activity through inhi-
bition of viral or cellular polymerases by acting as low-effi-
ciency substrates. Low rates of incorporation of nonnatural
nucleosides can result in polymerase “stalling” (16), chain ter-
mination, or lowered rates of replication from templates con-
taining modified nucleosides (23). Thus, the observed antiviral
activity may result, at least in part, from a reduction in RNA
replication kinetics caused by inhibition of the viral RdRp.
However, this effect is likely minor considering the fairly rapid
kinetics of incorporation of these analogs relative to ribavirin
(Table 3).
While the concentrations of nucleoside analogue used in these
studies may be considered high for therapeutic application, the
proposed mechanism of action for these analogues (i.e., lethal
mutagenesis) implies competition with the intracellular pools of
natural nucleotides. Particularly, these analogues act as general
purine analogues, indicating they would need to compete against
the extraordinarily high intracellular concentrations of ATP and
GTP (approximately 3 mM total purine nucleotides) (34). Fur-
thermore, the mutagenic effect we have documented at these
concentrations is substantial, and these analogues may in fact
provide relevant antiviral effects at lower concentrations, because
continuous exposure should lead to accumulation of mutations
over multiple rounds of genome replication. With regard to ther-
apeutic relevance, the only clinically employed nucleoside ana-
logue proposed to act via antiviral lethal mutagenesis is ribavirin,
which is dosed at extraordinarily high concentrations during treat-
ment (in the range of 1 g per day) and can accumulate to con-
centrations approaching 0.5 mM in the liver (7).
While we have demonstrated that the active nucleoside an-
alogues identified in this work are not efficient substrates for
RNR in vitro, conversion to the deoxyribonucleotide may still
be possible through nucleotide phosphorolysis, liberating the
nucleobase to be available as a substrate for phosphoribosyl
transferase and allowing for generation of the deoxyribo-
nucleosides through nucleobase salvage. Furthermore, the ri-
bonucleosides themselves may exert toxicity through inhibition
of, or incorporation by, cellular RNA polymerase II or mito-
chondrial polymerases. Further exploration of the interaction
of mutagenic nucleosides with cellular polymerases is neces-
sary to understand the clinical implications of treatment with
antiviral lethal mutagens.
Recently, modified bases of JA23 and JA27 were shown to
inhibit hepatitis C virus replication when attached to a 2-C-
methyl ribose (14, 15). However, those compounds were found
not to function as substrates for adenosine kinase, with admin-
istration of a cyclic monophosphate prodrug increasing efficacy
significantly. While the templating specificity of these 2-C-
methyl ribonucleotide analogues has not been directly eluci-
dated, some variability in the nucleobase can be tolerated
without loss of antiviral activity (8). Therefore, the use of
nucleobases with ambiguous hydrogen bonding properties,
such as those described herein, may allow chain termination to
be exerted in the context of two or more templating bases.
Furthermore, the lack of phosphorylation activity observed by
Gunic et al. (14) may explain, at least in part, the lack of
activity of related analogues in the present study.
In summary, we have identified nucleoside analogues which
can act as antiviral lethal mutagens against picornaviruses. An
increase in the frequency of transition mutations was observed,
presumably due to tautomerization of the modified nucleo-
bases leading to two distinct hydrogen bonding acceptor/donor
surfaces which can interact favorably with either of the natural
pyrimidines. Furthermore, these nucleosides had favorable
properties in terms of polymerase incorporation and cellular
metabolism and appeared not to be recognized as substrates
FIG. 7. Antiviral activity of nucleoside analogues against a high-
fidelity PV variant (PV-G64S). Infections were performed at an MOI
of 5 and treatment with 2 mM nucleoside analogue. Infection was
allowed to proceed for 6 h at 37°C, and cell-associated virus was
collected by freeze-thaw. (A) The titer of virus was determined on
HeLa S3 cell monolayers. Data were normalized for each virus such
that the virus titer resulting from untreated control infection was set
equal to 100. Data are plotted as the means and standard deviations
from three independent samples. (B) Virus was assayed for the Guar
phenotype as described in the text. Results are reported as means and
standard deviations from three independent samples. Due to the small
amount of viable virus recovered from JA30-treated samples, n  2 for
wild-type (WT) PV and n  1 for PV-G64S for this treatment only.
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for mammalian ribonucleotide reductase. Thus, these modified
nucleosides represent important lead compounds in the devel-
opment of antiviral lethal mutagens for clinical use.
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